Date: 2012-05-02
Type of information: Distribution agreement
Compound: defibrotide
Company: Gentium (Italy) PharmaSwiss, (Switzerland), a division of Valeant Pharmaceuticals International (Canada)
Therapeutic area: Digestive diseases - Liver diseases - Transplantation
Type agreement: distribution
Action mechanism: Defibrotide is a polydeoxyribonucleotide isolated from pig intestine. It is believed to have antithrombotic properties.
Disease: prevention and treatment of hepatic veno-occlusive disease (VOD)
Details: Gentium has announced the appointment of PharmaSwiss S.A., a division of Valeant Pharmaceuticals International, Inc., as the exclusive distributor of defibrotide in the following territories: Albania, Bosnia, Bulgaria, Croatia, Cyprus, Czech Republic, Greece, Hungary, Macedonia, Montenegro, Poland, Romania, Serbia, Slovenia and Slovakia.
Under the terms of the agreement, which is valid for 10 years, PharmaSwiss will be responsible for managing named-patient requests and achieving price and reimbursement approvals in these territories. Following regulatory approval to market defibrotide, if any, PharmaSwiss will be responsible for sales, marketing and local medical affairs activities in these countries.
Financial terms:
Latest news:
